Key result
Twice-daily oral sibrafiban provided sustained inhibition of platelet aggregation (trough concentrations 54% of peak), unlike once-daily dosing which caused high peak-trough excursions.
Why the study?
What are the pharmacokinetic and pharmacodynamic profiles of oral sibrafiban in patients with acute coronary syndrome?
Population
Patients post-acute coronary syndrome
Design
Other
Follow-up
up to 28 days
Authors
Loading...
Twice-daily sibrafiban sustains consistent platelet inhibition in ACS; extends PK/PD rationale to inform dosing in efficacy trials.
What are the pharmacokinetic and pharmacodynamic profiles of oral sibrafiban in patients with acute coronary syndrome?
Twice-daily dosing of oral sibrafiban provides more sustained inhibition of platelet aggregation and less peak-trough excursion compared to once-daily dosing in post-ACS patients.
Modi et al. (1999) studied acute coronary syndrome. Sibrafiban was evaluated on Pharmacokinetics and pharmacodynamics. Twice-daily oral sibrafiban provided sustained inhibition of platelet aggregation (trough concentrations 54% of peak), unlike once-daily dosing which caused high peak-trough excursions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: